This report was first published by Endpoints News. To see the original version, click here
The oncology field is buzzing after a landmark readout from Revolution Medicines, known colloquially as RevMed, showed that a targeted “pan-RAS” drug doubled the survival time for patients whose pancreatic cancer has returned or stopped responding to previous treatment. As cancer researchers and drugmakers head to San Diego this weekend for the annual AACR meeting, here’s what we’re watching:
→ RevMed will be reporting more data at AACR, both on its drug daraxonrasib as well as another KRAS-targeted therapy zoldonrasib. The Phase 1/2 daraxonrasib readout will give an updated look at how the drug fares as a first-line treatment in metastatic pancreatic cancer, both alone and alongside chemotherapy. Revolution Medicines reported an initial cut of data in the first-line setting last year, showing overall response rates of 47% and 55% alone and with chemotherapy respectively.